31 – 40 of 88
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression
(
- Contribution to journal › Article
-
Mark
Atomoxetine restores the response inhibition network in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures
(
- Contribution to journal › Article
-
Mark
Genome-wide association study of the modified stumvoll insulin sensitivity index identifies BCL2 and FAM19A2 as novel insulin sensitivity loci
(
- Contribution to journal › Article
-
Mark
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
(
- Contribution to journal › Article
- 2015
-
Mark
The role of the amygdala during emotional processing in Huntington's disease : from pre-manifest to late stage disease
(
- Contribution to journal › Article
-
Mark
Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals
(
- Contribution to journal › Article
-
Mark
Improving response inhibition in Parkinson's disease with atomoxetine
(
- Contribution to journal › Article